Cargando…

Beneficial Pleiotropic Antidepressive Effects of Cardiovascular Disease Risk Factor Interventions in the Metabolic Syndrome

BACKGROUND: Although the increased prevalence and severity of clinical depression and elevated cardiovascular disease risk represent 2 vexing public health issues, the growing awareness of their combined presentation compounds the challenge. The obese Zucker rat, a model of the metabolic syndrome, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Frisbee, Stephanie J., Singh, Sarah S., Jackson, Dwayne N., Lemaster, Kent A., Milde, Samantha A., Shoemaker, J. Kevin, Frisbee, Jefferson C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907597/
https://www.ncbi.nlm.nih.gov/pubmed/29581223
http://dx.doi.org/10.1161/JAHA.117.008185
_version_ 1783315563767922688
author Frisbee, Stephanie J.
Singh, Sarah S.
Jackson, Dwayne N.
Lemaster, Kent A.
Milde, Samantha A.
Shoemaker, J. Kevin
Frisbee, Jefferson C.
author_facet Frisbee, Stephanie J.
Singh, Sarah S.
Jackson, Dwayne N.
Lemaster, Kent A.
Milde, Samantha A.
Shoemaker, J. Kevin
Frisbee, Jefferson C.
author_sort Frisbee, Stephanie J.
collection PubMed
description BACKGROUND: Although the increased prevalence and severity of clinical depression and elevated cardiovascular disease risk represent 2 vexing public health issues, the growing awareness of their combined presentation compounds the challenge. The obese Zucker rat, a model of the metabolic syndrome, spontaneously develops significant depressive symptoms in parallel with the progression of the metabolic syndrome and, thus, represents a compelling model for study. The primary objective was to assess the impact on both cardiovascular outcomes, specifically vascular structure and function, and depressive symptoms in obese Zucker rats after aggressive treatment for cardiovascular disease risk factors with long‐term exercise or targeted pharmacological interventions. METHODS AND RESULTS: We chronically treated obese Zucker rats with clinically relevant interventions against cardiovascular disease risk factors to determine impacts on vascular outcomes and depressive symptom severity. While most of the interventions (chronic exercise, anti‐hypertensive, the interventions (long‐term exercise, antihypertensive, antidyslipidemia, and antidiabetic) were differentially effective at improving vascular outcomes, only those that also resulted in a significant improvement to oxidant stress, inflammation, arachidonic acid metabolism (prostacyclin versus thromboxane A(2)), and their associated sequelae were effective at also blunting depressive symptom severity. Using multivariable analyses, discrimination between the effectiveness of treatment groups to maintain behavioral outcomes appeared to be dependent on breaking the cycle of inflammation and oxidant stress, with the associated outcomes of improving endothelial metabolism and both cerebral and peripheral vascular structure and function. CONCLUSIONS: This initial study provides a compelling framework from which to further interrogate the links between cardiovascular disease risk factors and depressive symptoms and suggests mechanistic links and potentially effective avenues for intervention.
format Online
Article
Text
id pubmed-5907597
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59075972018-05-01 Beneficial Pleiotropic Antidepressive Effects of Cardiovascular Disease Risk Factor Interventions in the Metabolic Syndrome Frisbee, Stephanie J. Singh, Sarah S. Jackson, Dwayne N. Lemaster, Kent A. Milde, Samantha A. Shoemaker, J. Kevin Frisbee, Jefferson C. J Am Heart Assoc Original Research BACKGROUND: Although the increased prevalence and severity of clinical depression and elevated cardiovascular disease risk represent 2 vexing public health issues, the growing awareness of their combined presentation compounds the challenge. The obese Zucker rat, a model of the metabolic syndrome, spontaneously develops significant depressive symptoms in parallel with the progression of the metabolic syndrome and, thus, represents a compelling model for study. The primary objective was to assess the impact on both cardiovascular outcomes, specifically vascular structure and function, and depressive symptoms in obese Zucker rats after aggressive treatment for cardiovascular disease risk factors with long‐term exercise or targeted pharmacological interventions. METHODS AND RESULTS: We chronically treated obese Zucker rats with clinically relevant interventions against cardiovascular disease risk factors to determine impacts on vascular outcomes and depressive symptom severity. While most of the interventions (chronic exercise, anti‐hypertensive, the interventions (long‐term exercise, antihypertensive, antidyslipidemia, and antidiabetic) were differentially effective at improving vascular outcomes, only those that also resulted in a significant improvement to oxidant stress, inflammation, arachidonic acid metabolism (prostacyclin versus thromboxane A(2)), and their associated sequelae were effective at also blunting depressive symptom severity. Using multivariable analyses, discrimination between the effectiveness of treatment groups to maintain behavioral outcomes appeared to be dependent on breaking the cycle of inflammation and oxidant stress, with the associated outcomes of improving endothelial metabolism and both cerebral and peripheral vascular structure and function. CONCLUSIONS: This initial study provides a compelling framework from which to further interrogate the links between cardiovascular disease risk factors and depressive symptoms and suggests mechanistic links and potentially effective avenues for intervention. John Wiley and Sons Inc. 2018-03-26 /pmc/articles/PMC5907597/ /pubmed/29581223 http://dx.doi.org/10.1161/JAHA.117.008185 Text en © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Frisbee, Stephanie J.
Singh, Sarah S.
Jackson, Dwayne N.
Lemaster, Kent A.
Milde, Samantha A.
Shoemaker, J. Kevin
Frisbee, Jefferson C.
Beneficial Pleiotropic Antidepressive Effects of Cardiovascular Disease Risk Factor Interventions in the Metabolic Syndrome
title Beneficial Pleiotropic Antidepressive Effects of Cardiovascular Disease Risk Factor Interventions in the Metabolic Syndrome
title_full Beneficial Pleiotropic Antidepressive Effects of Cardiovascular Disease Risk Factor Interventions in the Metabolic Syndrome
title_fullStr Beneficial Pleiotropic Antidepressive Effects of Cardiovascular Disease Risk Factor Interventions in the Metabolic Syndrome
title_full_unstemmed Beneficial Pleiotropic Antidepressive Effects of Cardiovascular Disease Risk Factor Interventions in the Metabolic Syndrome
title_short Beneficial Pleiotropic Antidepressive Effects of Cardiovascular Disease Risk Factor Interventions in the Metabolic Syndrome
title_sort beneficial pleiotropic antidepressive effects of cardiovascular disease risk factor interventions in the metabolic syndrome
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907597/
https://www.ncbi.nlm.nih.gov/pubmed/29581223
http://dx.doi.org/10.1161/JAHA.117.008185
work_keys_str_mv AT frisbeestephaniej beneficialpleiotropicantidepressiveeffectsofcardiovasculardiseaseriskfactorinterventionsinthemetabolicsyndrome
AT singhsarahs beneficialpleiotropicantidepressiveeffectsofcardiovasculardiseaseriskfactorinterventionsinthemetabolicsyndrome
AT jacksondwaynen beneficialpleiotropicantidepressiveeffectsofcardiovasculardiseaseriskfactorinterventionsinthemetabolicsyndrome
AT lemasterkenta beneficialpleiotropicantidepressiveeffectsofcardiovasculardiseaseriskfactorinterventionsinthemetabolicsyndrome
AT mildesamanthaa beneficialpleiotropicantidepressiveeffectsofcardiovasculardiseaseriskfactorinterventionsinthemetabolicsyndrome
AT shoemakerjkevin beneficialpleiotropicantidepressiveeffectsofcardiovasculardiseaseriskfactorinterventionsinthemetabolicsyndrome
AT frisbeejeffersonc beneficialpleiotropicantidepressiveeffectsofcardiovasculardiseaseriskfactorinterventionsinthemetabolicsyndrome